NEXT GENERATION ANTIBODY THERAPEUTICS
Improving antibody directed delivery of cargo
iProgen has developed a proprietary and powerful antibody delivery technology platform which can be used to design innovative first-in-class drugs for unmet medical needs.
Our goal is to advance select drug candidates into clinical development to demonstrate the benefits of our technology platform and fostering broad industry adoption.
ANTIBODY DRUG CONJUGATE
A critical factor in developing a successful Antibody Drug Conjugate (ADC) is the antibody’s ability to internalize once it binds to the cancer cell’s target-receptor. Although some cancer cell-specific receptors internalize the antibody efficiently following binding (e.g. EGFR2), many cancer cell receptors (e.g. CD20) do not internalize antibodies efficiently.
iProgen has developed a proprietary antibody engineering technology that enhances antibody delivery and internalization. When this technology was applied to ADC, it has shown a significant improvement in in-vivo efficacy in several mouse xenograft models.